Zobrazeno 1 - 7
of 7
pro vyhledávání: '"E. G. Kosolapov"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 12-24 (2018)
Background. The modern therapies of advanced melanoma include targeted medicines for patients with BRAF mutations. Nowadays, a new perspective on immuno-oncologic medicine pembolizumab became available in Russia. Objective. Assessment of the clinical
Externí odkaz:
https://doaj.org/article/7ac86788063a41b4ac2ea06a10df591c
Autor:
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 22-30 (2017)
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial
Externí odkaz:
https://doaj.org/article/1d4f89ad2f9c43b4acf1d67df41135bb
Autor:
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 12-21 (2017)
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inha
Externí odkaz:
https://doaj.org/article/510e92d40fef4d478021f3c82e9a7a72
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 31-40 (2017)
In accordance with currently accepted recommendations for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), both monotherapy with long-acting anticholinergics (LAAC) or combined therapy (LAAC / long-acting beta-agonists, LA
Externí odkaz:
https://doaj.org/article/45a3d1dabd4645ce9114c79e5fe8b0e7
Autor:
F. S. Kochenkov, N. L. Bondarenko, A. V. Karaulov, E. G. Kosolapov, D. V. Blinov, N. L. Pogudina
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 22-30 (2017)
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e2b340f150ad9be9f04351c24e2800
https://www.pharmacoeconomics.ru/jour/article/view/196
https://www.pharmacoeconomics.ru/jour/article/view/196
Autor:
F. S. Kochenkov, E. G. Kosolapov, N. L. Bondarenko, D. V. Blinov, A. V. Karaulov, N. L. Pogudina
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 12-21 (2017)
Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management. Study objective : to identify the preferable FDC of in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c09ed9c2928a26f1b7ca738a027c9f8
https://doi.org/10.17749/2070-4909.2017.10.2.012-021
https://doi.org/10.17749/2070-4909.2017.10.2.012-021
Publikováno v:
Фармакоэкономика, Vol 10, Iss 2, Pp 31-40 (2017)
In accordance with currently accepted recommendations for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), both monotherapy with long-acting anticholinergics (LAAC) or combined therapy (LAAC / long-acting beta-agonists, LA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6169d274a474f28ead14baa001d4bbe
https://doi.org/10.17749/2070-4909.2017.10.2.031-040
https://doi.org/10.17749/2070-4909.2017.10.2.031-040